Key result
Dabigatran is an effective and safe oral direct thrombin inhibitor for preventing thrombosis in orthopedic surgery and stroke in atrial fibrillation, offering stable anticoagulation without periodic laboratory monitoring.
Dabigatran is an effective oral anticoagulant for stroke prevention in atrial fibrillation and post-orthopedic surgery thrombosis, though it remains contraindicated in end-stage renal disease and lacks evidence for mechanical heart valves.
Dabigatran may simplify anticoagulation in AF without monitoring; leaves open comparative safety versus other agents in broader populations.
Dabigatran is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. It has been approved in the European Union and the United States of America for the prevention of thrombosis after major orthopedic surgery. It has also been approved by the American Food and Drug Administration and the European Medicines Agency for the prevention of stroke in chronic atrial fibrillation. Dabigatran provides a stable anticoagulation effect without any need to perform periodical laboratory controls. Of note, there is a growing amount of clinical evidence which shows its safety and efficacy. For these reasons, dabigatran may suppose a revolution in oral anticoagulation. However, two important limitations remain. First, it is contraindicated in patients with end-stage renal disease. Second, there is no evidence of the prevention of thrombosis in mechanical heart valves.
No takes yet. Share an insight, caveat, or question.
Redondo et al. (2011) conducted a review in Thrombosis and Atrial Fibrillation. Dabigatran vs. Vitamin K antagonists or Enoxaparin was evaluated. Dabigatran is an effective and safe oral direct thrombin inhibitor for preventing thrombosis in orthopedic surgery and stroke in atrial fibrillation, offering stable anticoagulation without periodic laboratory monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: